Consensus Decision Pathway News Today

This clinical quiz will test your knowledge on management of LDL-C special populations with nonstatin therapies based on the ACC's 2022 expert clinical decision pathway.

This clinical quiz will test your knowledge on the use of non-statin therapies for LDL-C lowering based on the American College of Cardiology's 2022 Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.

A panel of cardiologists discuss the key updates from the 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-C lowering in the management of atherosclerotic cardiovascular disease risk.

New data from the phase 2 ROSE2 trial is providing insight into the safety and tolerability, as well as LDL-lowering effects, of obicetrapib as an adjunct to high-intensity statin therapy as a monotherapy and in combination with ezetimibe.

- Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p - 87.1% of Patients Treated with Combination of Obicetrapib and Ezetimibe Met Guideline-Recommended LDL-C Goal of - New Data Demonstrate

In this episode of Don’t Miss a Beat, hosts sit down at ESC HFA to discuss key takeaways from the ACC's expert clinical decision pathway and preview HFpEF data scheduled to be presented during the meeting.

Dr Michos offers strategies to successfully reduce LDL levels in patients with cardiovascular disease.

Erin Michos, MD, MHS, opens a discussion surrounding the utilization of bempedoic acid for patients with intolerance to statin-based therapies.

If subsequently approved, Entresto will be the first and only approved therapy for the treatment of symptomatic chronic heart failure patients aged 1 to <18 years in the European Union Pediatric... | March 31, 2023

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Entresto receives positive CHMP opinion for pediatric heart failure